REGENERON PHARMACEUTICALS, INC. (REGN) Total liabilities 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) total liabilities at each fiscal year-end, per SEC filings.
$9.3BFY2025 · since FY2016: $2.5B → $9.3B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $9.3B | +10.7% |
| FY2024 | $8.4B | +18.3% |
| FY2023 | $7.1B | +8.5% |
| FY2022 | $6.6B | -1.7% |
| FY2021 | $6.7B | +8.6% |
| FY2020 | $6.1B | +65.2% |
| FY2019 | $3.7B | +24.8% |
| FY2018 | $3.0B | +13.6% |
| FY2017 | $2.6B | +3.8% |
| FY2016 | $2.5B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More REGN financial trends
REGN RevenueREGN Net incomeREGN Net marginREGN Gross profitREGN Gross marginREGN Operating incomeREGN Operating marginREGN Operating cash flowREGN Free cash flowREGN Capital expendituresREGN Return on equityREGN Stock buybacksREGN Dividends paidREGN Total assetsREGN Shareholders’ equityREGN overview →